Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir

Journal of Infectious Diseases

Volumn 183, Issue 4, 2001, Pages 523-531

  Gubareva, Larisa V ^a   Kaiser, Laurent ^a   Matrosovich, Mikhail N ^b,c   Soo Hoo, Yee ^a   Hayden, Frederick G ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COMPLEMENTARY DNA; OSELTAMIVIR; PLACEBO;

ADULT; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; EXPERIMENTAL INFECTION; HUMAN; INFLUENZA; INFLUENZA VIRUS; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; VIRUS INFECTION; VIRUS MUTANT; VIRUS RESISTANCE;

ACETAMIDES; ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; CELL LINE; DOGS; DRUG RESISTANCE, MICROBIAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PLAQUE ASSAY; RECEPTORS, VIRUS; VARIATION (GENETICS);

EID: 0035865919     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/318537     Document Type: Article

References (39)

1. Influenza virus neuraminidase inhibitors
2. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en
3. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en
4. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en
5. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase
6. Mucins and mucoids in relation to influenza virus action. III. Inhibition of virus haemagglutination by glandular mucins
7. Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium: The role of the host cell in selection of hemagglutinin receptor specificity
8. Specification of receptor-binding phenotypes of influenza virus isolates from different hosts using synthetic sialylglycopolymers: Non-egg-adapted human H1 and H3 influenza A and influenza B viruses share a common high binding affinity for 6′-sialyl(N-acetyllactosamine)
9. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates
10. Receptor specificity of influenza A viruses correlates with the agglutination of erythrocytes from different animal species
11. Sialyloligosaccharides of the respiratory epithelium in the selection of human influenza virus receptor specificity
12. Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses
13. Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection
14. Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: Implications for vaccine manufacture
15. Generation and characterization of variants of NWS/G70c influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en
16. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en
17. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en
18. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071
19. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir
20. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus
21. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment
22. Plaque inhibition assay for drug susceptibility testing of influenza viruses
23. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro
24. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate
25. Comparison of two nested PCR, cell culture, and antigen detection for the diagnosis of upper respiratory tract infections due to influenza viruses
26. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140
27. Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses
28. Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses
29. Analysis of the host-specific haemagglutination of influenza A(H1N1) viruses isolated in the 1995/6 season
30. Clinical influenza virus and the embryonated hen's eggs
31. A host-cell-selected variant of influenza B virus with a single nucleotide substitution in HA affecting a potential glycosylation site was attenuated in virulence for volunteers
32. The HAI of cold-adapted influenza B vaccine is not altered during replication in human vaccinees
33. Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice
34. Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: A study by reverse genetics
35. Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism